Furiex Pharmaceuticals, Inc.NASDAQ
FURX is defunct.
  • Apr. 28, 2014, 8:27 AM
    • Forest Labs (FRX) acquires Furiex Pharmaceuticals (FURX) for $95/share ($1.1B) in cash and up to $30/share in a Contingent Value Right (CVR) payable on the regulatory approval of eluxadoline.
    • Forest will divest Furiex's royalties on alogliptin and Priligy to Royalty Pharma for $415M which will reduce its purchase price by ~$315M (after tax).
    • Furiex shares are up 26%┬ápremarket on robust volume.
    | Apr. 28, 2014, 8:27 AM
  • Feb. 19, 2014, 12:11 PM
    • Bloomberg reports Furiex Pharma (FURX +6.5%) has hired BofA/Merrill to help find a buyer. Shares have spiked higher in response.
    • Two weeks ago, Furiex more than doubled in response to news its Eluxadoline irritable bowel syndrome drug had met the company's main objectives in a late-stage study.
    | Feb. 19, 2014, 12:11 PM